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E X E C U T IV E  S U M M A R Y
Field-based investments in Research and Innovation for global health has the potential to achieve 
improve people's health in low and middle income countries. The Research & Innovation Principle paper 
outlines objectives broadly seek to leverage local and international research and implementation 
expertise to:
•  Discover innovative ways of delivering services that reduce cost, increase access, and improve 
quality of care;
•  Hasten implementation of successful interventions at scale, including adapting and replicating 
successful models from one setting to another; and
• Develop local capacity for identifying research needs, developing appropriate research activities, 
implementing, evaluating, and publishing research findings in the peer-reviewed literature.
This paper summarizes the US Government's position on promoting Research and Innovation in global 
health, provides guidance to missions on how to successfully support Research and Innovation in the 
field, and tap into technical support for such activities in USG Agency Headquarters. Illustrative 
(optional) and global (required) indicators for monitoring and evaluating Research and Innovation are 
provided, as are related resources to help position field staff for rapid uptake of this key principle.
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P R E F A C E
The United States Presidential Global Health Initiative (GHI) outlined seven fundamental principles ito 
guide the U.S. Governments (USG) strategy, policy, and programs in current and future global health 
efforts. These principles normatively reflect how the USG works towards achieving global health 
priorities and health targets.
The inclusion of the Promote Research and Innovation Principle underscores two critical shifts in global 
health thinking. First, evidence must guide and underpin policy, practice, and strategy decisions in global 
health. The global community expects accountability demonstrated by evidence that links investments 
to health outcomes with greater emphasis on efficiency and sustainability. Evidence to inform and drive 
effective, efficient, sustainable global health interventions, services, programs, and systems linking 
investments to outcomes is a core purpose of promoting research and innovation. Secondly, 
globalization combined with scientific advances has accelerated the rate of scientific exchange and 
multiplied the potential for global collaboration and local innovation while simultaneously bringing the 
challenges in resource scarce areas into greater focus.
Over time the application of the Principle to Promote Research and Innovation, will improve the 
efficiency, effectiveness, and sustainability of global health services, interventions, and programs and 
lead to accelerated progress towards USG Global Health goals, including achieving an AIDS Free 
Generation by 2015, reaching the GHI Targets , and ending preventable child deaths as outlined in A 
Promise Renewed". The application of this Principle will also facilitate the development of high impact 
research agendas and the translation of research results into global public health benefit.
P U R P O S E
The purpose of this Principle paper is to share information, guidance, ideas, resources, challenges, and 
experiences with U.S. Government (USG) country teams on how to apply the Promotion of Research and 
Innovation (R&I) principle in their programs to accelerate progress towards the USG and partner country 
health goals. The paper includes information on how USG field teams can obtain technical support from 
the science and development agencies within the USG.
Vision: A sustained commitment to applying learning from research and innovation will result in 
accelerated progress towards reaching global health goals and provide transparent evidence linking 
USG global health investments and health impact
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O V E R V IE W
This paper begins with the rationale for USG efforts to promote research and innovation in USG global 
health initiatives and programs. It continues with the definitions of research, innovation, evaluation, 
and monitoring all of which play a role in learning.
The next section describes the six objectives which comprise the evidence cycle and includes general 
recommendations, shared experiences, and suggestions on how to achieve the objectives, optimize 
resources, and enhance collaboration across the USG at the country level. Specific recommendations 
linked to suggested resources are provided in the appendices. The paper continues with how to 
measure progress in advancing research and innovation. It also conveys technical support potentially 
available to the USG teams in the field to advance research, innovation, and translation of results into 
sustainable health impact and sustainable research capacity.
R A T IO N A L E
Years of investment in scientific capacity have made the United States one of the most productive 
scientific societies in the world. This scientific progress, such as the development of effective 
antiretroviral therapy for HIV/AIDS, has contributed to improved global health outcomes through 
effective USG global health delivery programs such as PEPFAR1". Yet the full potential of translating 
scientific investments and leveraging scientific discovery for health impact has yet to be fully realized. 
Translating results from research and innovation is particularly challenging for the world's most 
vulnerable populations in the lowest economic quintile, in distant rural areas, or crowded impoverished 
slums. In an era of fiscal constraint, the global community is pressed to deliver more health value, 
defined as improved health outcomes for dollars spent. The USG is committed to strategically 
leveraging global health investments across all agencies, and the comparative advantage of each, for 
greater global public health impact in USG global health endeavors.
Globalization and innovation create opportunity for accelerated translation of science, technology, 
research, and innovation into global health impact. Future global health advances should continue to be 
evo lu tionary  -  e.g. accelerating scaling of evidence-based health services to populations without access 
and also revolu tionary  -  leap frogging previous sequential stepwise single discipline progress with 
multidisciplinary scientific and technological approaches to create novel, sustainable solutions for the 
world's most pressing health challenges.
Innovation is needed to generate new ideas and more effective means of doing things. Research is 
needed to test innovative approaches and provide evidence on effectiveness. Implementation research 
informs how to efficiently and effectively scale-up novel health services to populations in a sustainable 
manner and to show attribution of investments to outcomes. Globalization facilitates contribution from 
local problem solvers who can identify local challenges and solutions to facilitate the delivery, and
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utilization of evidence based efficacious health care. The USG encourages research and program 
investments to concurrently improve the both the evidence-base and the application of key knowledge 
and practices through operational research and implementation science. Special focus is encouraged to 
strengthen the integral connections between research activities, their innovative application in 
programs, and the achievement of health goals.
The USG Promotion of Research and Innovation Principle supports leveraging the full U.S. Government 
science and development communities in collaboration with host country governments, public health 
institutions, universities, and a new community of solvers to achieve global health gains. The USG global 
health goals (e.g. an AIDS-Free Generation and GHI targets) are most likely to be achieved through 
collaboration between the scientific community, the development community, and host country 
institutions and governments. To achieve these goals requires innovative solutions and application of 
scientific and technical advances that translate advances such as mobile telephones and internet into 
health benefits through innovative programming this is evaluated through implementation science. The 
ability of Missions and USG country Teams to enable such innovations in their programs is crucial to 
success.
Finally, the USG is committed to partnering with countries to work towards sustainable country owned 
global health. Therefore, the promotion of research and innovation includes a focus on building 
sustainable research and innovation capacity to enable countries to establish and execute an ongoing 
evidence cycle for their health priorities.
Globalization and innovation create opportunity for accelerated translation o f science, 
technology, research, and innovation into global health impact.
D E F IN IT IO N S  O F  R E S E A R C H  A N D  IN N O V A T IO N
Broadly, research can be defined as the systematic application of scientific methods to generate novel 
findings. The continuum of research ranges from basic early stage to applied late stage research 
designed to efficiently and effectively implement novel findings or interventions outside of a research 
setting. Over the past decade, in an attempt to improve the efficiencies in global development 
programs, the field of implementation science has evolved as a study of methods to improve the uptake, 
implementation, and translation of research findings into routine and common practices outside the 
research setting (e.g. the ''know-do'' or ''evidence to program'' gap) (Padian, 2011). The USG 
President's Emergency Plan for AIDS Relief (PEPFAR) introduced an implementation science framework 
in 2011 to facilitate causal attribution of programs to outcome in order to advance the "value and 
impact" of PEPFAR programs. Many USG teams are now accustomed to the PEPFAR implementation 
science framework and this Principle Paper builds on these definitions.
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The PEPFAR implementation science framework includes three elements: monitoring and evaluation, 
operations research, and impact evaluations (Padian, 2011). Monitoring is the "routine daily assessment 
of ongoing activities, inputs, outputs, and progress while evaluation assesses what has been achieved" 
(The Global Fund to Fight AIDS, Tuberculosis and Malaria, 2008) and is not research for the purposes of 
this paper and reporting. In contrast, operations research and impact evaluations are considered to be 
research. Operations research involves "increasing efficiency of implementation and operational 
aspects of a particular program through the use of scientifically valid research methods" (The Global 
Fund to Fight AIDS, Tuberculosis and Malaria, 2008, Madon, 2007, Padian, 2011). Impact evaluations 
enable causal attribution of observed changes in outcomes to a particular program by comparing these 
changes with what would have happened had the program not been implemented (the counterfactual 
scenario) (Padian, 2011). Impact evaluations should include value assessments whenever possible, (e.g., 
health outcomes per dollars spent) to enable cost effective comparisons. Cost effectiveness is an 
important element of sustainability for resource constrained countries. For the purposes of this 
guidance, USG teams should consider promoting research and innovation activities which advance 
health impact and outcomes, value for health, and address the "know-do gap". In general this will not 
encompass early stage laboratory focused studies, nor therapeutic and device development.
•  Global Health Research: For the purposes of this guidance, late stage1 research is intended to 
develop evidence which maximizes the impact of USG global health activities on health 
outcomes. Such research generally includes operations research, impact evaluations, and other 
research that supports accomplishing the USG global health goals with the highest priority given 
to those with the most immediate health impact within a 3 to 5 year time period. This includes 
studies of innovation, effectiveness, impact, and sustainability.
•  Global Health Innovation: Innovation is a novel way of making or doing things including novel 
business or organizational models, operational or production processes, technologies or 
products or services that lead to substantial improvements in the effectiveness, efficiency, or 
sustainability of a global health activity. Global health activities include systems, services, 
interventions, and programs on both the supply and demand side. Thus innovation can take 
place outside of the formal health system, within the formal health system, within the 
community health system, or within the community itself. Innovation is not limited to 
development of novel technologies; it can also be a novel approach or application of a 
technology, service, or intervention.2
1 The US Foreign Assistance Office defines three research areas which are defined and treated as "linked key issues" which are 
mutually exclusive for reporting purposes: Basic Research (BSR), Applied Research (APR), and Development Research (DVR). 
These tree areas are predominately defined by systematic study directed towards differing aims:1) to gain knowledge or 
understanding necessary to determine the means by which a specific need may be met-Applied Research (APR) 2) to obtain 
fuller knowledge or understanding of the fundamental aspects of phenomena and of observable facts-Basic Research, and 3) 
application of knowledge for production of useful materials, devices, and systems or methods including design, development, 
and improvement of prototypes and new processes to meet specific requirements-development research.
2 Note: Programs that simply make use of innovative solutions are not included within this Key Issue unless they are explicitly 
aimed at accelerating the rate at which novel solutions are developed, tested and scaled.
1 2
D r a f t  f o r  P u b lic  C o m m e n t M a y  8 , 2 0 1 3
•  M onitoring and Evaluation: Monitoring is the routine assessment of ongoing activities, inputs, 
outputs, and progress while evaluation assesses what has been achieved and does not generally 
employ scientific methods to determine outcomes or impact relative to a counterfactual as in an 
impact evaluation (The Global Fund to Fight AIDS, Tuberculosis and Malaria, 2008). For the 
purpose of this paper, routine programmatic monitoring and evaluation are not considered 
'research' or 'innovation'. Please see the USG M&E Principle paper for additional guidance in 
this important area.
Given the importance of context for determining health needs and solutions, it is anticipated that USG 
field supported research, as opposed to headquarters supported research, will focus on improving the 
value and impact of USG supported country owned programs. Likewise, local higher education learning 
institutions, research centers, and private technology companies provide opportunities for local 
innovation to address context specific local challenges and solutions needed to facilitate the delivery 
and utilization of evidence based efficacious health care.
S T R A T E G IC  O B J E C T IV E S  & T H E  E V ID E N C E  C YC LE
This principle paper suggests a simple strategic approach to promoting research and innovation by 
contributing to and using evidence to maximize the impact of USG global health activities on health 
outcomes. This strategic approach involves six objectives (Box 1.) that together comprise the Evidence 
Cycle characterized in the Results and Innovation Framework (Figure 1).
Box 1. SIX OBJECTIVES of the EVIDENCE CYCLE
I. Develop an enabling environment for research and innovation
II. Establish an effective knowledge management system
III. Identify country-specific research & innovation priorities (and/or
agenda)
IV Design & procure evidence based programs & embed prioritized
research and innovation activities
V. Identify and apply research and innovation learning to programs,
policies, and evidence base
VI Quantify improved value and accelerated progress towards the USG
global health targets
These objectives are intended to help country teams promote the collaborative incorporation of 
research, innovation, as well as evaluation and monitoring, into an evidence cycle for of continuous, 
evidence-based quality improvement, innovation, and translation of learning into sustained population 
level health impact.
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Recommendations and suggested indicators for each Objective are included in Appendix II. 
Recommendations are intended to be useful and most are non-obligatory. Once the R&I indicators are 
finalized, teams will be required to report on the indicators identified as "Global Indicators" in the 
Monitoring and Evaluation portion of this paper. USG teams do not have to apply these objectives (nor 
the framework) in a sequential fashion, as the evidence cycle is cyclical, but it may be useful to do so.
Figure 1. The Research and Innovation Results Framework is based on developing and applying novel 
evidence generated during the "Evidence Cycle". The Framework aligns with six objectives.
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OBJECTIVE I: D evelop  an Enab ling  E n v iro n m e n t fo r  Research and  In n o va tio n  
Overview
An enabling environment in the USG missions and in the host country is the foundation of efforts to 
promote research and innovation. To facilitate ease of understanding this section is divided into two 
parts: 1) developing an enabling environment at the USG Missions, and 2) developing an enabling 
environment in the host country.
Box 2. Common Challenges Developing a Research and Innovation Environment
•  Lack of knowledge of all the activities of USG agencies in a particular country or 
area such as nutrition, as there is no single, central knowledge source. This is 
particularly true between research and development agencies (e.g. NIH and 
USAID) but can also be true between development agencies, e.g. USAID and 
MCC, and within agencies, e.g. HHS CDC and NIH. Lack of communication and 
coordination lead to redundancies and/or missed opportunities for synergy, cost 
sharing, and efficiencies.
• No visible health Research & Innovation contact at USG Mission
• USG staff may not identify Research & Innovation as a priority for development.
• USG researchers, even those working internationally, often do not recognize the 
importance of development priorities in their work and have little contact with 
the USG Missions.
•  Government responsibilities for health, science, technology, and education are 
often divided between ministries.
Developing an Enabling Environment for Research and Innovation at USG Missions
The Enabling R&I Environment at the Mission is a critical component of promoting R&I in country and 
should include the presence of at least one R&I 'coordinator' responsible for managing country specific 
R&I responsibilities. USG teams may also choose to align the coordination vertically with specific health 
areas, e.g. nutrition, or malaria. In such cases USG teams should be aware of opportunities for program 
integration which lead to greater efficiencies. The R&I Coordinator should serve as the point-of-contact 
for R&I related activities and this function should make up a significant portion of their work-plan. 
Though the entire USG team assumes responsibility for planning all aspects of the evidence cycle, the 
R&I coordinator will organize the team to support the global health R&I activities and report on 
progress. As part of their knowledge management function, the R&I coordinator should compile, with 
headquarters assistance, the USG supported health research projects, including sites which are part of 
USG supported research and innovation networks3, taking place in the country including studies funded 
by the USG (e.g. USAID, Millennium Challenge Corporation, Centers for Disease Control, U.S. President's 
Emergency Plan for AIDS Relief, Department of Defense, and the National Institutes of Health etc.). This
3 The USG increasingly supports a wide range of global health research and innovation networks which may be valuable sources 
of technical assistance to both the USG mission and the host country governments, Examples include, but are not limited to: 
USAID's Higher Education Solutions Network http://www.usaid.gov/hesn , NICHD's Global Network for Women's & Children's 
Health Research https://www.nichd.nih.gov/research/supported/Pages/globalnetwork.aspx
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USG research list can be updated on an annual basis with the help of USG contacts in Washington, D.C. 
and the field. The R&I coordinator can also help facilitate host country research partners by reaching 
out and coordinating involvement with local universities, medical schools, research institutes, health 
professional associations, and USG supported implementing partners and research networks. Additional 
recommendations for the R&I Coordinator activities are included in Appendix II.
Creating an Enabling Environment for R&I in the Host Country
In keeping with the principles of 
integration and country ownership, USG 
teams should collaboratively engage key 
host country stakeholders, leverage 
existing country owned research capacity, 
and facilitate sustainable research 
capacity while promoting research and 
innovation. Research and Innovation 
stakeholders usually include policy 
makers, relevant government sectors (e.g.
Ministry of Health, Ministry of Science 
and Technology, or Ministries of Finance) 
national academies of science, research 
institutions, multilaterals, universities, 
and, where relevant, the private sector.
Some countries, for example India, Kenya, 
and South Africa, have significant 
research infrastructure and expertise and 
serve as regional health research leaders.
Thus, teams are encouraged to engage 
local and regional expertise to the full 
extent possible (see Recommendation
1.5) Although some countries will have 
extensive sustainable R&I infrastructure, some countries may have limited technical expertise and 
research capacity. Thus, it is imperative for USG efforts to continue to support higher education and 
training in the public health fields particularly in disciplines such as: epidemiology, nursing, medical, 
research, midwifery etc. Working with local research and innovation institutions facilitates development 
of sustainable research capacity.
In order to inform the development of a research and innovation plan and build upon existing activities, 
the R&I coordinator should lead an assessment of current scientific research and innovation activities, 
infrastructure, training plans, and needs. The results of this assessment will inform development and 
prioritization of the research and innovation agenda. Though the nature of the host country 
environment for R&I can vary greatly, early engagement of local stakeholders in knowledge 
management and priority setting for research and innovation will facilitate improved translation into 
health impact after new knowledge results from R&I activities.
Box 3. Building local research capacity while 
leveraging USG science investm ents to  accelerate 
solutions for child survival
The Partnerships for Enhanced Engagement in Research 
(PEER) was created by USAID to leverage research 
capacity and investments in science developed by USG 
science agencies for development challenges. In 2012, 
the first PEER Health solicitation created opportunities 
for developing country researchers to partner with 
National Institutes of Health (NIH) funded researchers on 
challenges related to child health implementation 
science. PEER Health provides opportunities for USAID 
Missions to engage with local universities, research 
institutes, and NIH supported investigators. Leadership 
and financial responsibility of PEER projects rest with the 
developing country scientists and their local institutions, 
enhancing local capacity to respond to research 
solicitations, manage grants, and undertake cutting edge 
implementation science activities.
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A little knowledge that acts is worth more than much knowledge that is idle." 
Kahlil Gibran, A u thor o f  The Prophet 
"Knowledge for the most part exists only in application."
P eter Drucker, A u thor o f  The E ffective Executive
Overview
In order for the research and innovative learning to be used, adapted, and scaled, it is essential for USG 
Country Teams to have access to and contribute to a knowledge management (KM) plan. Effective 
knowledge management involves development and sharing of global and local evidence and 
information. Thus, a country KM plan includes two parts: 1) global knowledge management 2) country 
specific knowledge management. Organizing and coordinating knowledge and information reduces 
duplication, avoids reliance on outdated information, and shortens the time it takes to find, adapt and 
use knowledge to improve or expand health programs. Effective KM is a critical component of reducing 
costs, increasing value, stimulating innovation, and promoting at-scale implementation of evidence- 
based programs and practices.
Global Knowledge M anagem ent
Global knowledge is gained from the collective experience of research and innovation across all 
countries and provides opportunities to learn from multiple contexts and various country perspectives. 
The headquarters knowledge management plan is a catalyst for sharing, synthesizing, and learning from 
the collective experience, thus enabling countries to leverage what they know works in other countries.
As acknowledged in the initial GHI Monitoring, Evaluation, Research, and Innovation USG paper in 2009, 
the burden of responsibility for creating a comprehensive USG knowledge management system to 
capture both data and best practices falls on participating Agencies at Headquarters. The KM staff 
contributes to the "research to practice"' process by:
>  Collecting all potential "innovative" models resulting from research, program management 
and/or other sources, including those outside the health sector.
>  Collecting and making public documented best practices, evaluations, funded research 
publications, results of funded research and innovation conferences or consultations.
>  Conducting a periodic review and summary of evidence derived from global health programs 
that assess the feasibility and cost-effectiveness of new models and archiving these into a 
system that would allow for open access and widespread proactive dissemination.
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>  Supporting professional discussion (threaded bulletin boards or chat rooms) for staff to
ask/answer questions and/or have longer term discussions on specific applications/adoptions of 
models to the field.
Country Knowledge M anagem ent Plan
To effectively use Global Knowledge Management, each USG country team should also develop and 
implement a country knowledge management plan that brings together key country data, ongoing 
research and innovation activities, cost effectiveness data, and other relevant knowledge for each global 
health target or goal. The ultimate goal should be to optimize the sharing, adaptation and use of 
knowledge resources that connect best practices and innovative health interventions, services, and 
products with immediate health challenges such as malaria incidence, drug resistance patterns, disease 
prevalence information, and local program experiences.
To support strengthened health research and innovation USG implementers and their partners must 
share actionable information and knowledge generated locally to address challenges and improve 
program results with the headquarters Global Knowledge Management system, and with the global 
community via publications and effective dissemination strategies for their successes such as electronic 
regional technical meetings, and the like, so countries may learn from one another.
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OBJECTIVE III :  Id e n tify  C ountry -S pec ific  Research &  In n o v a tio n  P r io rit ie s  
O v e rv ie w
Ideally a document which outlines multi-year, country specific, public, research and innovation priorities 
(which may or may not be considered an RI agenda) achieves two important aims: 1) identification of 
critical country specific evidence gaps and implementation challenges, and 2) inclusion of a plan to 
address key R&I priorities. Publically available R&I priorities help to identify, clarify, and communicate 
the locally relevant research and innovation priorities that when addressed will result in accelerated 
progress toward global health goals and targets. Doing so will help create demand to address identified 
priorities in the public and private sector. Examples of priorities might include the need to deliver 
scalable innovations such as oral rehydration salts or Option B+ to a particular geographic region or 
population, or the scale of other interventions to reduce postpartum hemorrhage, or malnutrition.
Research and  In n o v a tio n  P r io rit ie s
R&I priorities must reflect country host country public health priorities and challenges. In some 
countries the R&I priorities may already be publically apparent in an R&I Agenda, or within the USG 
strategy or country national research priorities. In others countries, the USG team may need to facilitate 
development of such priorities. Ultimately a publically available R&I agenda should facilitate 
collaboration across multiple donor countries, or in some cases different USG agencies. The process of 
identifying priorities or developing an agenda should be informed by knowledge management and 
developed with stakeholders including country governments, local research and public health 
institutions, national academies of science, and other relevant stakeholders. Ideally the R&I priorities 
are already identified by national public health leadership. Further, R&I priorities should clearly 
articulate specific problems to be addressed; evidence needed, and anticipated impact on public health 
targets, and goals.
Transparent research and innovation priorities have the additional benefit of communicating priorities 
to the research and innovation communities both locally and across the USG. Therefore, making R&I 
priorities publically available can facilitate cost effective coordination across the USG, country 
stakeholders, and other bilateral and multilateral donors working in R&I in the country. The R&I agenda 
may be developed as a separate document or included in the Country Development Cooperation 
Strategy or as an addendum to the GHI Country Strategy. Teams should also consider placing a time 
frame on priorities, e.g. R&I activities attainable in the next five years.
Developing the R&I agenda can be a mechanism for drawing relevant stakeholders to global health 
priority challenge areas. One mechanism that USG teams may use to inform R&I priorities is convening 
technical experts around specific challenges, e.g. neonatal sepsis, behavior change science, nutrition, or 
the need to scale specific innovations. Consultations should always include local scientists, institutions, 
as well topical experts, and may take the form of a 'Science for Development" meeting or expert 
consultation as desired (See Appendix IV and Box 4 for more info on the Science for Development 
Meetings). Such consultations may help USG teams identify relevant evidence, knowledge gaps, and the 
local technical assistance needed around country health research priorities, and ultimately close the gap 
between novel evidence and policy.
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Box 4. USG Science for D evelopm ent M eeting in Mali
In January 2012, the USG team in Mali organized a Science for Development meeting. 
Drawing more than 100 participants, it was the first meeting of its kind to be held in 
Africa and served as an important occasion to build upon decades of U.S. 
Government internal collaboration within Mali, strong partnership with the 
Government of Mali, and collaborative research between Malian and U.S. scientists.
It gave participants an opportunity to explore ways in which the introduction of 
research, innovation, and new technologies can drive and influence development 
work in Mali. The meeting advanced the coordination, utilization, and application of 
existing knowledge, identified evidence gaps, and leveraged the scientific community 
to support the advancement of key Malian health development goals in five areas: 
HIV, tuberculosis, malaria, neglected tropical diseases, and health systems 
strengthening. The Malians established a Scientific Advisory board to the Ministry of 
Health and over thirty Malian scientists volunteered their technical services to the 
USG mission.
Priorities for the introduction and scale-up of evidence-based, effective 'innovations' in the host country 
should be data driven and targeted toward local priority health areas. Innovations do not have to be an 
entirely new approach but could be a modification of approaches already in existence. Once an 
innovation has been shown to have a positive performance outcome, decisions should be made to 
determine if the innovation meets criteria for further investment and scale. When identifying priority 
approaches, teams are encouraged to consider the cost-effectiveness of the intervention, means to 
integrate the intervention with existing health system, testing needed to determine success of adoption, 
and sustainability of proposed intervention or approach. The Center for Accelerating Innovation and 
Impact within the Global Health Bureau at USAID can be consulted for advice around adoption and scale 
up of innovations.
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OBJECTIVE IV: D esign and  P rocu re  Evidence-B ased P rogram s w ith  Em bedded  Research and  
In n o v a tio n  A ctiv ities
O v e rv ie w
Evidence underpins all effective USG programming and forms the basis of good program design. The 
'Evidence Cycle' is heavily featured in the R&I strategic framework and illustrates an iterative cycle of 
designing programs in line with country specific R&I priorities which lead to new evidence, best 
practices, and ultimately a new generation of programs and potential R&I priorities based on the 
acquired evidence (R&I Framework, boxes 2-5). While health impact is the primary aim of health 
programming, the generation of new evidence is a critical component within the program cycle.
Ensuring that learning "loops back" to inform the continuous dynamic improvement of programs, is 
essential for accelerating progress towards the global health targets and goals. Thus, research and 
innovation activities should be incorporated or 'embedded' into USG programs with the goal of 
producing high-quality context specific evidence to inform future and current USG supported health 
policy and programming efforts. In particular, USG teams should support research that bridges the gap 
between evidence-based services and their effective implementation with the goal of improving the 
health "value" of USG investments. As outlined in Objective I, when possible these research activities 
should be done in collaboration with local technical expertise and HC governments.
D es ig n in g  evidence-based  p ro g ram s
"Demand Evidence and Think Critically" is a common refrain in scientific fields. However, ensuring that 
programmatic learning adheres to the same level of rigor and defining the bar for 'evidence' is often 
difficult in the complex environments where USG global health teams operate. Additionally 
understanding the type of evidence needed to answer a specific question is also important in order to 
choose the appropriate type of research study.
Em bedded  research  and  in n o v a tio n  a c tiv ities
The successful introduction and scale of innovative programs requires embedding active learning to 
ensure optimal program implementation and causal attribution of program implementation to 
outcomes and impact. "Learning" encompasses standard monitoring and evaluation, in addition to 
various types of research such as: operations research, impact evaluations, qualitative research, and 
other types of studies. For example, in order to determine if an innovation will have value, a pilot study 
must be conducted to assess performance or impact measures relative to standard-of-care or standard 
approach. All USG agencies and contract organizations carrying out these types of research activities 
should liaise closely with USG health teams responsible for program implementation. Open access peer­
review publications are a desired outcome of all types of research and USG teams and implementing 
partners should plan for authorship at the research design phase. Failure to publish in peer review 
journals jeopardizes the information, the financial investment in the research, and can lead to the 
repetition of the research elsewhere.
The fundamental principles of rigorous research are important for all USG supported research including 
independent review of protocols to include: study design, appropriate comparators, human subject 
protections, and statistical analysis plans including adequate power when appropriate to ensure the 
study will adequately address the primary study questions. USG health teams overseeing research
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activities classified as human subject research are encouraged to host protocol review in conjunction 
with a local Institutional Review Board.
USG teams are encouraged to develop (or request) a plan for publication and authorship ensuring that 
local scientists and innovators have a leadership role in the design, implementation, and publication of 
R&I activities. Leveraging local scientific and technical expertise in the design and implementation of 
R&I activities promotes sustainable research capacity, strengthens science and development linkages, 
and facilitates the critical research to applied learning "feedback loop."
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OBJECTIVE V: Share and  A p p ly  R & I L e a rn in g  to  P rogram s an d  Policies  
O v e rv ie w
Upon completion of R&I activities, it is critical that the knowledge gained is communicated and applied. 
The "feedback loop" linking research and innovation results to service, training, policy, and programs is 
critical to promote improved quality and accountability in health programs. Assuming R&I activities were 
collaboratively planned with key stakeholders via the development of the R&I priorities, translating the 
results to policy and action will be a natural next step. All USG research should be undertaken with the 
goal of accelerating progress to the targets and goals, therefore, using the results to advance these 
targets through more effective programs become a natural part of the learning cycle.
A sustained commitment to applying learning from research and innovation will result in 
more effective, sustainable service delivery programs over time.
C o m m u n ica tin g  Research and  In n o v a tio n  Results
Teams must ensure that USG supported R&I activities and results are published in a peer review open 
access journal, thus contributing to an evidence base that others can both use and build on. USG teams 
are encouraged to follow the publication plan developed during the design process. It is important to 
publish results even if they are negative findings, e.g. an innovative approach to delivery of nutritious 
food was not effective due to unpalatable taste. If the results are not published the knowledge will not 
be optimally utilized and over time, forgotten, which wastes resources. Similarly, the results should be 
maintained in the country knowledge management system and shared with the HEADQUARTERS Global 
Knowledge Management System. Assuming the research and innovation activities undertaken were 
derived from the collaboratively developed R&I priorities/agenda, stakeholders in the agenda and/or in 
the design and conduct of the research itself can help communicate the results and incorporate the 
learning into improved health programs and or systems.
A p p ly in g  th e  resu lts
Though research published in peer reviewed journals contributes to the evidence base and facilitates 
knowledge sharing, publishing alone will not accrue health benefit in the field. When well designed, 
USG-supported research and innovation results should inform and advance progress towards the USG 
health targets including strengthening existing, and identifying new, sustainable, cost-effective service 
delivery programs; overcoming barriers to implementation and system scale-up; facilitating the 
development and expansion of improved and integrated health interventions and systems; improving 
health value; and informing improved health policies. A sustained commitment to applying learning 
from research and innovation will result in more effective, sustainable service delivery programs over 
time. Further, as USG teams collaboratively execute against the country R&I priorities/agenda, the 
priorities/agenda will need to be revisited and revised accordingly. Teams may wish to hold periodic R&I 
meetings where results and revisions are collaboratively discussed with stakeholders.
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OBJECTIVE V I: Q u a n tify  A cce le ra ted  Progress to w ard s  th e  USG targ e ts  
O v e rv ie w
Transparent accountability for clearly communicating the relationship between global health 
investments and health impact has become a standard expectation in global health. The USG is 
committed to reporting progress in both the USG targets and the impact of the principles on the targets. 
The overall vision is that sustained learning from research and innovation will improve global health 
decision making and programs leading to greater health value and accelerated progress in reaching 
country specific USG targets and goals. USG research and innovation is not "research for research sake". 
Rather USG R&I in the field should advance country specific USG targets as articulated in the definition 
of USG Research.
To capture and quantify the impact of R&I learning, USG country teams must be cognizant of the 
changes resulting from the new evidence being put into practice and assess the anticipated impact of 
the new evidence on health targets. Teams may find it useful, and perhaps necessary, to use modeling 
or percentages of enhanced efficacy, efficiency, coverage, access, health value etc. to determine the 
impact of the R&I over time. USG teams are encouraged to use the quantitative measures related to the 
specific health targets, e.g. GHI targets, AIDS free generations, etc.
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M E A S U R IN G  R E S E A R C H  A N D  IN N O V A T IO N
O v e rv ie w
The USG is committed to transparency of results. An overall monitoring and evaluation goal is to 
understand the contribution of the seven principles to success as measured by progress towards the 
USG targets and improving health value (health impact per dollars spent). Below are listed 'Global' (i.e. 
reportable) indicators as they relate to key R&I Objectives. Additional illustrative indicators are listed in 
Appendix I. Teams will find specific recommendations for each objective in the tables in Appendix II.
G lobal In d ica to rs
Objectives Global Indicator
I Develop an enabling environment for research and 
innovation
Publically Identified Research and 
Innovation coordinator(s) (Y /N )
II Establish an effective knowledge management 
system
III Identified country-specific research & innovation 
priorities (and/or agenda)
Publically available country- 
specific Research and Innovation 
priorities (and /or agenda)
IV Design & procure evidence based programs & 
embedded prioritized research and innovation 
activities
% of mission health budget spent 
on health research activities
V Identify and apply R&I learning to programs policies 
& evidence base
# of peer review publications that 
include a local collaborator 
resulting from USG funding
VI Quantify accelerated progress towards the USG 
global health targets
Table 2 : Each objective forms part of the evidence cycle and is supported by suggested 
recommendations (Appendix II). There are five suggested indicators and three global (reportable) 
indicators (bolded) and two illustrative (optional) indicators within the R&I Framework. Two are 
foundational to progress and three measure improvement over time.
In d ica to rs
The first two indicators, "Identified R&I Coordinator" and "Publically Available Collaborative Research & 
Innovation Priorities/Agenda" are simple dichotomous indicators and considered foundational for 
promoting R&I activities. Teams are encouraged to communicate the contact information for the R&I 
Coordinator and the R&I priorities/agenda in a public fashion via websites.
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The third indicator, "Percentage of mission health budget spent on health research activities" is 
intended to capture the output of, and commitment to, the R&I process. This will not capture the 
individual investments of some agencies, e.g. the NIH or the USDA. However, is should reflect the 
growing commitment to critical research and innovation in global health via the USG missions. The 
optimal percentage of mission budget allocated towards research will vary by program size and needs; 
in general countries are encouraged to target 3-8% towards research activities. It is important that 
teams include all the expenditures for various types of research in their calculation of total percentage 
expenditure. Research embedded in innovation to assess effectiveness, impact, and sustainability 
should be included in this total as well. The percentage should not include R&I research supported via 
Headquarters
The indicator, "number of protocols that include a local collaborator" captures the commitment to 
collaboration with local stakeholders and governments and to build sustainable research capacity. 
Reporting and/or tracking the number of peer review publications with a local collaborator reflects the 
commitment to: transparently building the evidence base by through scientifically standard process, 
communicating the results of R&I activities, collaborating with local scientific institutions, and building 
research capacity and country ownership for R&I.
I llu s tra tiv e  In d icato rs
Illustrative indicators that countries may find useful to track are listed in Appendices I.
S E E K IN G  T E C H N IC A L  A S S IS T A N C E
The US Government seeks to leverage all the US agencies' capabilities to advance and accelerate global 
health goals such as the GHI targets and Creating an AIDS-Free Generation. In keeping with the 
Quadrennial Diplomacy and Development Review (2010), the USG supports a "whole of government" 
approach to USG global health collaboration, coordination, thus leveraging of all USG agency resources. 
It is likely that USG mission teams will need technical assistance in advancing the Principle of Promoting 
Research and Innovation as suggested in this principle paper. There are at least three ways that teams 
may identify technical assistance for R&I activities from across the USG: 1) use the resources identified 
through Appendix III in this paper, 2) specific request placed through the Country Support Unit via the 
Country Coordinators, or 3) make a specific request through the new Office of Global Health Diplomacy 
by completing a USG Global Health Research and Innovation Technical Assistance Request form.
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Appendix I -Global and Illustrative Indicators
Global
(required)/
Illustrative
(optional)
Objective (s) 
measured Indicator Name Data Source Data Collection Method Target
Global Objective I Publically Identified Research and Innovation coordinator(s) (Y/N)
Research and 
innovation 
coordinator(s) scope 
of work ; Embassy 
staffing/org chart
Review of research and innovation 
coordinator(s) scope of work/role. Data will 
be collected on an annual basis.
Minimum 1 identified 
R&I Coordinator with 
50% LOE
Illustrative Objective I
Number of USG supported health research 
activities
Implementing
partner
records/documents
Data will be collected by reviewing 
implementing partner records. Research 
activities will be tracked at the Embassy level. 
Data will be collected on an annual basis.
Percent of Mission health research activities 
reflecting collaboration between two or more 
USG agencies in county
Percent of Mission health research activities 
reflecting collaboration with local research 
institutions and universities
Illustrative Objective II
Existence of a national and sub-national 
databases that enable stakeholders to access 
relevant data for policy formulation and 
program management and improvement
PEPFAR Report/WHO
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Illustrative Objective II
Existence of designated and functional 
institutional mechanism charge with analysis of 
health statistics, synthesis of data from different 
sources and validation of data from population 
and facility sources
PEPFAR/WHO
Global Objective III Publically available country-specific Research and Innovation priorities (and/or agenda)
Collaborative 
research and 
innovation priorities 
and/or agenda 
documentation
Country-specific R&I priorities and/or agenda 
can include a priority list or agenda that is 
country-led, USG-led or led collaboratively by 
country and USG.
Included in reporting requirements by 
Embassy. Data collected on an annual basis.
Yes
Illustrative Objective IV # of USG funded health research protocols that have a local collaborator
Implementing 
partner and US 
agency records
Reviewed = Refers to health research 
protocols that have undergone a technical 
expert review and an IRB ethical clearance 
review.
Included in reporting requirement by Embassy 
and implementing partners. Data collected 
on an annual basis.
Increase over time
Global Objective IV
Total dollar amount spent on health research by 
the Mission. Mission budget 
records, 
Implementing 
partner budget 
records
Data will be collected by reviewing mission 
health budget records and implementing 
partner budget records and dividing the 
amount of the health budget spent on 
research activities by the total amount of 
mission health budget for the past year. Data 
will be collected on an annual basis.
no target
Percentage of Mission health budget spent on 
Research activities
Approximately 3 to 8 
percent
Illustrative Objective IV Number and list of USG supported health innovations introduced in country
Implementing
partner
records/documents
Innovation = Is a novel way of making or 
doing things to improve the effectiveness, 
efficiency, or sustainability of a global health 
activity. Innovation is not limited to 
development of products, drugs, or 
diagnostics; it can also be a novel approach or 
application of a technology, service, or 
intervention.
Introduced = Refers to any new innovation 
not previously supported in country that is 
incorporated into USG health programming or 
the host country health system. Data will be 
collected by reviewing implementing partner 
records/documents to sum the number of 
innovations introduced in the country during 
the past year. Data will be collected annually.
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Illustrative Objective IV Number of health innovations developed locally with USG support
Implementing
partner
records/documents
Innovation = Is a novel way of making or 
doing things to improve the effectiveness, 
efficiency, or sustainability of a global health 
activity. Innovation is not limited to 
development of products, drugs, or 
diagnostics; it can also be a novel approach or 
application of a technology, service, or 
intervention. USG Support = Support through 
the Higher Education Solutions Network 
(HESN) , Grand Challenge Program, or other 
program. Data will be collected by reviewing 
implementing partner records/documents. 
Data will be collected on an annual basis.
Illustrative Objective V Number and list of health innovations being scaled in host country with USG funding
Implementing
partner
records/documents
Innovation = Is a novel way of making or 
doing things to improve the effectiveness, 
efficiency, or sustainability of a global health 
activity. Innovation is not limited to 
development of products, drugs, or 
diagnostics; it can also be a novel approach or 
application of a technology, service, or 
intervention. Data will be collected by 
reviewing implementing partner 
records/documents. Data will be collected on 
an annual basis.
Global Objective V and Objective I
# of peer review publications that include a 
local collaborator resulting from USG 
funding
Implementing 
partner records, 
research publications
Included in reporting requirements by 
Embassy and implementing partners. Data 
collected on an annual basis.
increase over time
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Objective 1: Developing an Enabling Environment for R&I by USG team
1.1 Identify at least one person within the team to serve as a R&I coordinator:
• Coordinator is responsible for helping the USG team promote optimal use of best available evidence and acquisition knowledge.
•  R&I designee should manage lists of research activities occurring in country
•  Health teams are encouraged to request and utilize the AAAS Science & Technology Policy fellows who may be available to 
spend a year or more at the mission as part of the overseas fellows program
1.2 Coordination among USG Agencies for R&I:
•  Obtain list of USG/Washington contacts from the Country Support Office at federal global health agencies to help coordinate in 
country research including contacts at the following: HHS/NIH, HHS/CDC, HHS/OGHA, State/OGAC, USAID, MCC
• Identify and compile ongoing USG supported global health research within the country to share with the USG team. It is not 
unusual for the USG agencies to be unfamiliar with research funded by other USG agencies.
•  Obtain list of former USG research trained individuals e.g. from Fogarty International Center (FIC) at NIH that reside and work 
in host country
See Appendix 4 for additional R&I Resources
1.3 Coordinate Research Efforts with Host Country
•  Generate local contacts relevant to Mission specific health priorities at local science academies, higher education learning 
institutions, and professional associations and provide a list to the USG team.
•  Create a list of local scientists with specific technical expertise who are willing to share their expertise with the USG team and 
the Ministries of Health. It is common for the local scientists to feel they do not have a mechanism to contribute their expertise 
to public health efforts within their own countries.
•  Take a lead in working on developing and executing the collaborative research and innovation plan
Objective 1: Developing an Enabling Environment for R&I in Host Country
1.4 Identify presence or plans for a National Health Research Plan
1.5 Collaborate with local educational institutions to ensure that USG funded health programs are leveraged for research, innovation, and 
degree programs for higher education
1.6 Support of research conducted toward USG target areas (e.g. HIV/AIDS, TB, Malaria, Nutrition, Maternal Health, etc.) in partnership 
with host country research institutes
1.7 Encourage policies requiring researchers to report results to USG teams and host country's relevant ministries.
1.8 Identify, support, and collaborate with relevant scientific advisory bodies utilized by the host country, such as the National Academies 
of Science. In the event that appropriate health research advisory groups do not exist, look for opportunities to assist in their
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formation, drawing upon existing scientific strengths in the country with a special emphasis on those researchers who have strong ties 
to international and USG research entities (e.g. the NIH, USDA, or the CDC).
1.9 Integration of policies and regulations to support research. Multiple organizations including government (national, state and district 
levels), health institutions, and community based organizations can play a significant role in facilitating or hindering research. 
Streaming and communicating guidance to the research community on country research policies and procedures can facilitate in 
country research.
Objective 2: Establishing an effective knowledge management system
2.1 USG Teams are encouraged to centralize demographic and health data that it can be drawn upon to determine the context in which 
interventions will be carried out and that will provide data to inform strategy and program development as well as evaluations. In 
addition to establishing a centralized repository of such data (including either the data or easily accessible references to the data, such 
as hyperlinks that can be followed to find up-to-date data sets), the USG team should ensure that the existence and location of these 
data is made known to those who can use it in decision making. USG Teams are encouraged to seek information on evidence based 
services, interventions, and innovations to accelerate progress towards the USG targets. Each of the USG target areas has lists of up- 
to-date options for programs intended to reach USG targets. Key papers supporting many of the evidence based activities to
2.2 Data sets and information on best practices should be standardized to the extent possible, so that disparate data sets are more easily 
drawn upon for single analyses. This may entail requesting that program evaluations answer similar questions or produce data in 
similarly organized, machine readable formats, including the same meta-data with similar data sets (for example, how the data was 
collected, the time frame to which the data applies, or who produced it).
2.3 USG teams are encouraged to perform a mapping exercise that will result in knowledge of what USG-relevant data sets and knowledge 
are available (from USG, implementing partners, international organizations, NGOs, and others) and that will identify gaps that can be 
addressed through the research agenda.
Objective 3: Developing Country-Specific Prioritized R&I Agenda
3.1 Assessment of Host Country Research & Capacity
3.2 Convene in-country health scientists and program implementers around a specific health priority or priorities, e.g. neonatal sepsis, or 
around a specific challenge to global health targets and programming (high rates of post-partum hemorrhage, malaria resistance, low 
vaccination rates, or low use of modern contraception.
•  Invite USG experts to participate as needed. Depending on the topic and goals, this could be a Science for Development 
meeting as described elsewhere in this guidance. This activity would support a dynamic information flow between researchers, 
policymakers, and implementers regarding research evidence and/or global health program planning, improvement and 
innovation.
•  For example, if a country is considering expanding misoprostol for prevention of maternal hemorrhage after childbirth, 
convene an in country meeting of policy makers, implementers, and researchers to review evidence and plan implementation 
science needs. Doing so will ensure integration of all available evidence, identification of knowledge gaps and technical
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assistance needs, and enhance the implementation of research findings into policy in the future.
3.3 Draft country specific Prioritized Research and Innovation agenda To be maximally effective, it is suggested that the R&I plan follow the 
time tested S.M.A.R.T. approach towards setting R&I objectives: Specific, Measurable results, Attainable, Realistic, Time bound. For 
example, though developing a malaria vaccine is a meritorious goal, it would not be attainable for example with single country 
resources, in a short time frame. Suggested content should include:
•  Assessment of host country Research & Capacity
•  The identification of resource, technical gaps, evidence gaps, and implementation challenges.
•  Key research priorities for a given time frame
• Potential innovations to be scaled in a given time frame
• Priority actions to advance the research and innovation agenda in coordination with the host government
•  Plan to assess, ensure, and share progress. Specific timelines for each research priority and a quantitative assessment of how 
research and innovation plans will advance programming and targets.
Objective 4: Designing and procuring evidence based programs & embedded R&I activities
4.1 USG Teams should maintain a broad portfolio of research activities to inform programming including operational research, feasibility 
studies, epidemiological studies, and impact evaluations
4.2 Research and innovation activities should be embedded with the introduction and scale of innovations introduced in host country
4.3 USG Teams in host country should ensure that all Research Activities in Country compile with federal guidelines on human subjects 
protection, IRB, and ERC
Objective 5: Identifying and applying R&I learning to programs, policies, and evidence base
5.1 USG teams should track the progress of R&I activities in a transparent fashion enabling teams to understand when new results will be 
available.
5.2 Incorporating new evidence into programming may be straight forward, e.g. novel mobile phone communication strategy for post natal 
follow-up in a rural community or complex e.g. integration of intermittent preventive therapy for children under five into ongoing 
vaccination programs. USG teams should not hesitate to seek technical assistance from headquarters for interpretation and 
application of learning outcomes into programs.
5.3 Implementing partners and USG staff should publish research findings in peer-review journals rather than contributing to the gray 
literature
Objective 6: Quantifying accelerated progress to global health targets
6.1 USG teams should track the changes in programming and policies made on the basis of new evidence derived from R&I by health target 
area
6.2 USG teams should quantify the anticipated, and measure the actual, impact of the novel evidence on health outcome such as the seven 
USG target areas.
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A p p e n d ix  I I I .  Resources fo r  R & I O bjectives
Resource W ebsite Contact
Objective 1: Develop an Enabling Environment
Global Health Technologies Coalition: Why Investing in Global Health Research 
Works
http://www.ghtcoalition.org/fil 
es/ER GHTCPolicyReport2 fina 
l c.pdf
CDC Center for Global Health http://www.cdc.gov/globalheal
th/index.html
CDC Office of the Associate Director for Science (Science Quality and Integrity) See
guidance on Scientific Integrity
http://www.cdc.gov/od/scienc
e/index.htm
FDA, Office of Global Engagement:
Can help provide support to Mission health teams on overcoming regulatory hurdles.
US-FDA-
OGE@fda.hhs.gov
Fogarty International Center at the National Institutes of Health: Supports research 
training opportunities for global health researchers in developing countries. The 
Division of International Relations, FIC, can also be contacted to determine the 
number and scope of current FIC awards and NIH supported trainee by country.
http://www.fic.nih.gov/ Dr. Jim Herrington, 
Director of the 
Division of 
International 
Relations, FIC/NIH 
herringtonj@mail.nih. 
gov
Departm ent of State, Office of Global Health Diplomacy
Global Health Initiative http://www.USG.gov/
HHS, Office of Global Affairs http://www.globalhealth.govA
ndex.html
globalhealth@hhs.gov
HHS, Office of Global Health Research
NCI, Center for Global Health: Cancer is a leading cause of death around the world. 
NCI/CGH helps support NIH research efforts on the surveillance, prevention, and 
treatment of various cancers worldwide.
http://www.cancer.gov/aboutn Dr. Ted Trimble, 
Director
NCIGlobalHealth@mai
l.nih.gov
ci/globalhealth
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Resource W ebsite Contact
NCI, Tobacco Control Michele Bloch
NHLBI, Center for Global Health : NHLBI/CGH supports global health research on 
chronic disease at various research institutes around the world.
http://www.nhlbi.nih.gov/abou
t/globalhealth/
Cristina Rabadan- 
Diehl, Ph.D., M.P.H. 
Deputy Director 
rabadanc@nhlbi.nih.g 
ov
NIAID, Clinical Trials Network
NICHD, Office of Global Health: The OGH facilitates international research and 
coordinates the HIV/AIDS portfolio at the NICHD.
http://www.nichd.nih.gov/abo
ut/org/od/ogh/Pages/index.as
px
Dr. Vesna Kutlesic
kutlesicv@mail.nih.go
v
NIEHS, Center for Global Environmental Health: The Global Environmental Health 
Program assists the NIEHS in achieving its goals in three areas: Global Environmental 
Health Research, Global Environmental Health Translation, and Global Environmental 
Health Scientific Capacity.
www.niehs.nih.gov/geh Dr. John Balbus, 
Director
NIEHSGEH@mail.nih.g
ov
Global Health Technologies Coalition: 25 NGOs work to building support for global 
health technologies, conduct policy analysis to inform, develop and pursue strategic 
agenda for GHT, conduct outreach and pursue alliances, education and inform policy 
makers (based in Washington DC)
www. ghtcoaliti on.org/ab out- 
ghtc.Dho
info@ ghtcoalition.or
g
PEER Health program http://sites.nationalacademies.
org/PGA/dsc/peerhealth/index.
htm
Kelly Robbins
USAID M  Bureau, Library and Learning Resource Center http://inside.usaid.gov/m/cio/s
upport/service/librarv-
learning-resources-center
USAID TRACTION Project: Supports several USAID research projects around the 
world.
http://www.tractionproiect.org
/index.html
tracinfo@urc-chs.com
Objective 2: Establish an Effective Knowledge Managem ent System
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Resource W ebsite Contact
CDC Epi Info 7 and Epi Graph: downloads, tutorials and guides, translations (ex: 
French, Chinese, Spanish, Portuguese)
http://wwwn.cdc.gov/epiinfo/
CDC Learning Connection: Public health Informatics, Epidemiology, Surveillance and 
Statistics
http://www.cdc.gov/learning/i
ndex.html
CDC Science Clips an online bibliographic digest featuring scientific articles and 
publications that are shared to enhance awareness of emerging scientific knowledge.
http://www.cdc.gov/phlic/scicli
ps/
AID Data: A public database which plots donor investments (including USAID, World 
Bank, DFID) in development through geographic tagging.
http://www.aiddata.org/conte
nt/index
Clinical Trials.Gov: A website that maintains all approved USG supported clinical 
trials. Is searchable by country, region, or topic.
http://www.clinicaltrials.gov/
Demographic Health Surveys (DHS): Contains health and demographic data from 
over 300 surveys in over 90 countries. Reproductive Health Surveys
http://www.measuredhs.com
http://www.cdc.gov/reproducti
vehealth/Global/Surveys.htm
info@measuredhs.co
m
Knowledge for Health: A knowledge sharing website that contains health 
assessments, evidence, and the 'Implementing Best Practices' portal for researchers 
and practitioners to collaborate and share information. It also contains Popline, 
which is a searchable database of over 350,000 FP/RH publications and Photoshare, 
a searchable collection of free health and development photographs from around 
the world.
http://www.k4health.org/
Im plem entation Science Journal: Is an open access, peer-reviewed online journal 
that focuses on research relevant to the scientific study of methods to promote the 
update of research findings into routine healthcare in clinical, organizational or policy 
contexts.
http://www.implementationsci
ence.com/
M ultiple Indicator Cluster Surveys (MICS): Contains survey data on health, 
education, child protection and HIV/AIDS.
http://www.childinfo.org mics@unicef.org
NIH Reporter: A public database of all NIH supported research, which can be 
searched by country or research topic.
http://report.nih.gov/
UNICEF Country Statistics http://www.unicef.org/statistic 
s/index countrystats.html
USAID Development Experience Clearinghouse (DEC): A website that contains 
USAID project reports, evaluations and other relevant documentation on USAID
https://dec.usaid.gov/ ksc@usaid.gov
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Resource W ebsite Contact
projects dating back to 1946.
USAID GeoCenter: The GeoCenter works with Missions and operating units on 
planning, policy and learning activities by employing geographic methods and 
technologies to help USAID think spatially about its programs.
http://www.arcgis.com/apps/P
ublicGallery/index.html?appid=
143d06ca84d9447cb585e3a2ac
1c8e82&group=79306efcd11a4
1b3a2c3b261b0c09f9c
GeoCenter@usaid.gov
W HO Data and Statistics http://www.who.int/research/
en/
W orld Health Organization's Global Alert and Response System http://www.who.int/csr/en/
Objective 3: Develop Country-Specific USG Prioritized R&I Agenda
Guidance for Creating a Science for Development Meeting
Country Example of a USG Prioritized R&I Agenda
R&I Agenda Table of Contents Tem plate
Objective 4: Design and Procure Evidence-Based Programs and Embedded Prioritized R&I Activities
CDC Office of the Associate Director for Science (Science Quality and Integrity) http://www.cdc.gov/od/scienc
e/aboutus/index.htm
CDC Guidance on Scientific Integrity http://www.cdc.gov/od/scienc
e/docs/CDCSIGuideE02_16_12.
pdf
CDC Quality Resources: CDC Peer Review, Human Subjects Protection, Final Report 
Guidance, IRBs, training
http://www.cdc.gov/od/scienc
e/quality/resources.htm
CDC Integrity Resources: Public Health Ethics, Privacy and Confidentiality: legislation 
and regulations, Certificates and Assurance, Information Collection Review, Human 
Research Protections, Animal Care and Use
http://www.cdc.gov/od/scienc
e/integrity/
Agency Level Research Policy
Authorship Policy: CDC http://www.cdc.gov/maso/Poli
cy/Authorship.pdf
Peer-Review Policy: CDC http://www.cdc.gov/maso/pdf
/PeerReview.pdf
NIH/CDC/FDA Small Business Innovation Research and Small Business Technology 
Transfer programs (SBIR)
http://grants.nih.gov/grants/fu
nding/sbir.htm
CDC Innovation Resources http://www.cdc.gov/od/scienc
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Resource W ebsite Contact
e/innovation/resources.htm
Research Handbook
Research Protocol Guidance: CDC http://www.cdc.gov/od/scienc 
e/docs/CDCSIGuideE02 16 12. 
pdf
Advancing Excellence and Integrity of CDC Science: Innovation http://www.cdc.gov/od/scienc
e/quality/innovation.htm
USAID Human Subjects Research Guidelines http://transition.usaid.gov/poli
cy/ads/200/200mbe.pdf
Report to Congress: Health Related Research and Development Strategy, 2011­
2015
http://ghtcoalition.org/files/HR 
RStrategy web.pdf
Objective 5: Identify and Apply R&I Learning to Programs, Policies, and Evidence-Base
Evidence Summit Resources: Protecting Children Outside of Family Care http://www.hvcassistance.org/
summit.cfm
Evidence Summit: CHW Evidence Summit Final Report http://www.coregroup.org/sto 
rage/Program Learning/Comm 
unity Health Workers/chw%2 
0 evidence%20summit%20final 
%20report-19dec2012.pdf
Objective 6: Quantify Accelerated Progress Towards the USG Targets
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Appendix IV. General Guidance of Science for Development Meetings
Recommendations: "Science for Development Meetings"
Hosted by USAID Mission Directors and/or US Government Ambassadors
Elizabeth Higgs, USAID & Jim Herrington, NIH December 2011
Purpose: Science for Development Meetings facilitates field linkages between the USG supported 
research community and the US development practitioners. These meetings can take several shapes 
from informal "meet and greets" to a more structured program which may yield greater strategic 
results. This document includes suggested steps for hosting a meeting.
Background: Under the Global Health Initiative (USG) umbrella, the USG is committed to a whole of 
government, evidence based approach to achieving the USG health targets. Effective use of science, 
technology, and innovation is critical to the success of the Presidential Global Health Initiative (USG). 
During his May 5, 2009 announcement, President Obama stated, "We will not be successful in our 
efforts to end deaths from AIDS, malaria, and tuberculosis unless we do more to improve health systems 
around the world, focus our efforts on child and maternal health and ensure that best practices drive 
the funding of these programs." USAID Administrator Rajiv Shah underscored the importance of 
advancing science and innovation: "Science and technology innovations are critical drivers of g ro w th - 
some estimates attribute up to half of GDP gains to this kind of innovation. We will dramatically 
accelerate our efforts to solve major science, technology, and engineering challenges in development 
and engage the full federal science community in this effort."
USAID is committed to inclusive leadership and engaging the full federal science community to advance 
USG. USAID recognizes the critical importance of collaborating with in-country scientists and research 
institutions to support and advance the evidence base for efficient, effective, and sustainable health 
programs. Science for Development Meetings hosted by Mission Directors and/or US Ambassadors will 
initiate a dialogue with in-country NIH, DOD, CDC, and other USG supported researchers and other 
health innovators with the longer term goal of facilitating USG host country evidence-based programs to 
optimize health benefit to the populations needing them most.
M eeting Objectives: Objectives may vary depending on primary purpose of meeting
1) Communicate US Government development agenda and objectives to the host country health 
research and academic communities
2) Provide the mission directors and USG staff with a greater understanding of ongoing in-country 
research and innovation activities
3) Discuss how ongoing local research and public health institutions might be leveraged to support 
the USG principles and targets, e.g., "increase impact through strategic coordination and 
integration," and "encourage country ownership and invest in country-led plans."
4) Provide structured links with national researchers who can provide technical advice to the 
mission on research and innovation activities likely to advance USG goals, e.g. develop a 
prioritized research and innovation agenda
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5) Identify new health scientists and scholars who might benefit from linkages with the NIH, CDC, 
USDA, USAID etc. and their support mechanisms 
Possible Recommended Steps: Steps will vary depending on scope and primary purpose of meetings
1) Identify the POC at Fogarty International Center at National Institutes of Health to provide list of 
in-country current and former NIH supported trainees, researchers, and research institutions. 
USAID Headquarters can assist with this
2) Utilize in-country expertise and other resources to identify additional local resources without 
previous connections with the NIH
3) Issue an invitation to the identified researchers. For those accepting, request a one-two page 
over view of research and innovation activities, and how this might relate to public interest/ 
national health strategy.
4) Provide: a one to two page overview of USG, two page summary of USG country strategy, and 
overview of ongoing USAID supported research.
5) Identify Scientific Session lead in country
Potential Outcomes:
1) Database of local technical expertise and subject matter expertise
2) New applicants for NIH supported research and training
3) Development of standing links between the scientific community, the missions, and/or
government ministries
4) Identified specific health goals with integrated scientific and development work plans
5) Collaborative research and innovation agenda for USG
Illustrative Short M eeting Agenda
I. Welcome: USAID Mission Director or Ambassador
II. Introductions
III. Overview of USG Partnership effort, including principles and health targets
IV. Overview of Country Specific USG Objectives
V. Presentations by host-country scientists on their USG-funded research activities
VI. Open discussion on how local researchers and health scientists are supporting USG 
objectives and identify missed opportunities
VII. Open discussion on how USAID is supporting local research capacity, can foster country 
ownership, and identify innovative opportunities for host-country research to inform the 
USG development agenda
1 A ll se ven  p r in c ip le s  re fe re n c e d : h t tp : / /w w w .U S G .g o v /a b o u t /1 8 9 8 6 2 .h tm
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" President Obama reiterated the goals of an AIDS-Free Generation and saving children from preventable deaths 
http://www.theatlantic.com/politics/archive/2013/02/obamas-2013-state-of-the-union-speech-full-text/273089/ 
11 PEPFAR or the Presidential Emergency Plan for AIDS Relief was established in 2003 to help save the lives of those 
suffering from HIV/AIDS around the world. http://www.pepfar.gov..
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